It has been recognized recently that miRNA levels in the serum are exceptionally stable independent of age and sex of the detected subject, thus they hold great potential as disease markers in the clinical setting.[8] Unlike AFP with low sensitivity at early HCC stages, specific change of circulating miRNAs may appear early in cancer as a mechanism for functional regulation and early diagnosis. This evidence concerns the gene AFP and hepatocellular carcinoma.